H.C. Wainwright analyst Emily Bodnar raised the firm’s price target on AnaptysBio (ANAB) to $22 from $19 and keeps a Neutral rating on the ...

H.C. Wainwright adjusted its price target for Largo Resources Ltd. (NASDAQ:LGO) to $3.70, down from the previous $4.20, while maintaining a "Buy" rating on the stock. The firm's decision follows Largo ...

H.C. Wainwright analyst Douglas Tsao revised the price target for Sage Therapeutics (NASDAQ:SAGE) to $12.00 from the previous $14.00 while maintaining a Neutral rating on the company's shares. Tsao's ...

D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report)‘s stock had its “buy” rating reiterated by equities researchers at ...

H.C. Wainwright raised the firm’s price target on Coinbase (COIN) to $330 from $255 and keeps a Buy rating on the shares. President Donald ...

Investment analysts at HC Wainwright lowered their FY2028 earnings estimates for X4 Pharmaceuticals in a research note issued on Friday, February 7th. HC Wainwright analyst S. Ramakanth now forecasts ...

Fintel reports that on February 3, 2025, HC Wainwright & Co. initiated coverage of CRISPR Therapeutics (LSE:0VRQ) with a Buy recommendation. There are 575 funds or institutions reporting positions ...

In 2024 H.C. Wainwright also held the top position in PlacementTracker's Market League Tables for At-the-Market (ATM) Offerings representing 72 transactions. In addition to presently serving as ...

Fintel reports that on January 10, 2025, HC Wainwright & Co. initiated coverage of Bright Minds Biosciences (NasdaqCM:DRUG) with a Buy recommendation. As of March 27, 2023, the average one-year ...

(NASDAQ: KSCP), an innovator in robotics and artificial intelligence technologies focused on public safety, today announced that H.C. Wainwright & Co. has initiated coverage on the company with a Buy ...